AFFILIATIONS
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China, Zhejiang University Cancer Center, Hangzhou, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China
4 Huzhou Central Hospital, Huzhou, China
5 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China, Zhejiang University Cancer Center, Hangzhou, China
6 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China
7 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China
8 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China
9 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China
10 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China
11 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China
12 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China
13 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China
14 Weben Pharmaceutical Co., Ltd., Hangzhou, China
15 Weben Pharmaceutical Co., Ltd., Hangzhou, China
16 Weben Pharmaceutical Co., Ltd., Hangzhou, China
17 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China, Zhejiang University Cancer Center, Hangzhou, China
ABSTRACT
Introduction:
Despite advances in targeted therapies and novel treatment modalities, relapsed/refractory acute myeloid leukemia (R/R AML) continues to confer a dismal prognosis. A growing body of evidence implicates MYC dysregulation as an important driver in AML pathogenesis, contributing not only to uncontrolled proliferation and metabolic reprogramming but also to chemoresistance. Nevertheless, directly targeting MYC has remained a long-standing challenge in oncology, and no MYC-directed therapy has yet received regulatory approval. WBC100 is a first-in-class, orally bioavailable small-molecule glue degrader that penetrates the nuclear compartment and promotes proteasomal degradation of MYC protein, demonstrating robust antileukemic activity in preclinical mouse models of AML. Herein, we present the first clinical experience from an ongoing Phase 1 trial, reporting the safety profile, pharmacokinetics, and preliminary efficacy data of WBC100 in patients with R/R AML (WB002 Trial, NCT07014449).
Methods:
This ongoing Phase 1 study enrolled patients with R/R AML and Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 2 with adequate organ function. WBC100 was given orally once daily (QD) in 28-day cycles, with a 3+3 dose-escalation design spanning six dose levels (0.5, 1.0, 1.5, 2.0, 2.5, 3.0 mg), followed by an expansion cohort at 2.5 mg. Primary endpoints were safety and tolerability; treatment-emergent adverse events (TEAEs) were assessed per NCI-CTCAE v5.0. Secondary endpoints included efficacy, with responses [complete remission (CR), CR with partial hematologic recovery (CRh), CR with incomplete hematologic recovery (CRi), morphologic leukemia free state (MLFS) and minimal residual disease (MRD) negativity] assessed per ELN 2022 criteria after each cycle.
Results:
As of the July 20, 2026 data cutoff, 20 patients had been enrolled. The median age was 61 years (range, 23-71), and 45% were female. At baseline, the median time from diagnosis was 9 months (range, 2-43), with a median bone marrow blast count of 18% (range, 6-67%). Patients had received a median of 3 prior lines of therapy (range, 1-5); all had prior chemotherapy including cytarabine, and 19 (95%) had prior venetoclax exposure. TP53 mutations were documented in 3 patients (15%). Dose escalation from 0.5 to 3.0 mg QD revealed dose-proportional increases in systemic exposure, with minimal to no drug accumulation upon repeated dosing. At a median follow-up of 7.0 months, patients had received a median of one treatment cycle (range, 0.1–4.0).
No dose-limiting toxicities (DLTs) or tumor lysis syndrome (TLS) events were observed, and no treatment-emergent adverse events (TEAEs) led to dose discontinuation. Serious adverse events (SAEs) occurred in 45.0% (9/20) of patients, and grade ≥3 TEAEs occurred in 85.0% (17/20). The most common grade ≥3 TEAEs were decreased platelet count (70.0%), decreased neutrophil count (60.0%), anemia (30.0%), pneumonia (30.0%) and sepsis (20.0%). The 30-day mortality rate was 10.0%, all attributed to disease progression.
Among 15 efficacy-evaluable patients, the overall response rate (ORR) was 33.3% (5/15), comprising CR in 13.3% (2/15), CRh in 13.3% (2/15), MLFS in 6.7% (1/15), with an MRD-negative rate of 80.0%. Among the seven patients receiving 2.0 or 2.5 mg QD, the CR+CRh rate was 57.1% (4/7), with an overall response rate (ORR) of 71.4% (5/7). Notably, all four patients in the 2.5 mg QD cohort achieved an objective response (ORR 100%: CR 50%, CRh 25%, MLFS 25%). Remarkably, among the three TP53-mutant patients enrolled, the two evaluable cases both achieved CRh with MRD negativity. The median overall survival (OS) for all treated patients at 0.5–3.0 mg QD (n=20) was 4.9 months, and no patient proceeded to transplantation. However, OS data remain immature, with three patients still alive at data cutoff after approximately 3 months of follow-up. Evaluation of the recommended Phase 2 dose (RP2D, 2.5 mg) is ongoing.
Conclusion:
WBC100 demonstrated a generally manageable safety profile in adult patients with R/R AML. Notably, promising single-agent antileukemic activity was observed, with a 100% overall response rate in the 2.5 mg QD cohort.